Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Ties Increased Transfusions To ESA Scrutiny in NCD Review Request

Executive Summary

Amgen has released an internally generated analysis of data that draws a causal link between an increase in blood transfusions and the heightened scrutiny erythropoiesis-stimulating agents have received this year

You may also be interested in...

Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling

Amgen is expanding its pharmacovigilance program for Aranesp and Epogen with seven new clinical trials to study risks associated with using erythropoiesis-stimulating agents to treat anemia in patients with cancer

Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach

CMS has abandoned the idea of limiting some uses of erythropoiesis-stimulating agents to a research trial setting, despite receiving public comments that the "coverage with evidence development" approach may be acceptable in some circumstances

EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials

Sponsors of erythropoiesis-stimulating agents should conduct additional safety studies to support continued marketing in the oncology setting, FDA's Oncologic Drugs Advisory Committee unanimously recommends

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts